Friday, June 9, 2017
Menopause, Memory And Alzheimer’s Disease
When women think about menopause, they typically think about hot flashes. New research shows that memory problems are a common but under-recognized menopausal symptom.
Memory problems emerge during perimenopause, the time around the final menstrual period, before many women even realize that they are “going through the change.” Early research studies have documented an increase in memory complaints, such as forgetting names, as a woman enters the menopausal transition, while more recent studies have revealed measurable changes in verbal memory as a woman transitions through menopause [1, 2].
Although decreases in memory are a normal part of aging, age does not account for the changes in memory that occur when a woman transitions through menopause. Similarly, although sleep disturbances and mood symptoms are common and can affect memory, they do not account for memory problems during this transition. Preliminary research links memory problems to hot flashes, (when hot flashes are measured objectively ― using ambulatory monitors) but further research on this issue is needed [3,4]. The good news is that the memory problems that can emerge during perimenopause seem to improve during the postmenopausal years .
Hormonal factors appear to play a role in memory changes during the menopausal transition. The ovaries are the primary source of estrogen in premenopausal women. In women who have not yet reached their final menstrual period, having their ovaries surgically removed leads to a decline in verbal memory, which is reversed when they take estrogen therapy . Similarly, removing ovaries before age 48 has been associated with a 70 percent increased risk of cognitive impairment or dementia , but use of estrogen therapy until the typical age of menopause negates that risk.
When women are in their 50s and have transitioned through menopause, taking hormones does not seem to affect memory performance. For example, memory does not change when women begin hormone therapy within five years after their final menstrual period [6,7]. Meanwhile, initiating hormone therapy later in life – after age 65 – can actually increase the risk of memory problems and dementia [8,9]. It might be that women with hot flashes particularly benefit from hormone therapy. Initial evidence indicates that hormone therapy can improve memory and brain function in women with moderate to severe hot flashes , but more extensive studies are needed. Similarly, it is unknown how taking birth control pills containing estrogen can influence memory in perimenopausal women.
Women show a lifelong advantage in verbal memory compared to men. Interestingly, this advantage might make it more difficult for clinicians to detect a memory problem in women who are in the early stages of Alzheimer’s disease (AD). Before developing AD, patients transition though a stage called amnestic mild cognitive impairment, or aMCI. At this stage, memory problems exceed what is expected for age but do not reach the level of severity seen in AD. The female advantage in verbal memory persists in the aMCI stage. Consequently, women perform better than men despite showing the same level of AD disease on brain scans [11-13]. Although this could be seen as an advantage, women may be diagnosed with aMCI or AD at a later and more severe stage of the disease than men. Researchers are now exploring whether it might be useful for clinicians to use different cut-offs for memory tests in women and men, so that AD can be detected earlier in women.
Together, these studies demonstrate the important need to address how brain aging differs between women and men. By examining how menopause, estrogen, and other factors contribute to those differences, we can improve efforts to prevent, detect, and treat memory problems and memory disorders such as AD. This is especially relevant for women, who make-up 3.2 million out of the approximately 5 million individuals in the U.S. living with AD. It is estimated that the prevalence of AD will triple by 2050 , and the associated costs will exceed $20 trillion U.S. dollars. For this reason, it is imperative that we continue to work together to fund AD research and support studies that recognize and address the ways in which this deadly disease can affect women and men differently.
Story Source: The above story is based on materials provided by HUFFINGTONPOST
Note: Materials may be edited for content and length